Association Between Single-Nucleotide Polymorphisms in Hormone Metabolism and DNA Repair Genes and Epithelial Ovarian Cancer: Results from Two Australian Studies and an Additional Validation Set

• Published in: Cancer epidemiology, biomarkers & prevention biomarkers & prevention, 2007-12, Vol.16 (12), p.2557-2565
• Main Authors: BEESLEY, Jonathan, JORDAN, Susan J, GAYTHER, Simon A, PHAROAH, Paul D. P, WEBB, Penelope M, CHENEVIX-TRENCH, Georgia, SPURDLE, Amanda B, HONGLIN SONG, RAMUS, Susan J, KRUGER KJAER, Suzanne, HOGDALL, Estrid, DICIOCCIO, Richard A, MCGUIRE, Valerie, WHITTEMORE, Alice S
• Format: Article
• Language: English
• Subjects: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase - genetics; Australia; Biological and medical sciences; Case-Control Studies; DNA Repair - genetics; DNA Repair Enzymes - genetics; DNA repair genes; Female; Female genital diseases; Genetic Predisposition to Disease; Genotype; Gonadal Steroid Hormones - genetics; Gonadal Steroid Hormones - metabolism; Gynecology. Andrology. Obstetrics; hormone metabolism genes; Humans; Medical sciences; Neoplasms, Glandular and Epithelial - genetics; Neoplasms, Glandular and Epithelial - metabolism; ovarian cancer; Ovarian Neoplasms - genetics; Ovarian Neoplasms - metabolism; Polymorphism, Single Nucleotide; Reproducibility of Results; Risk Factors; SNP; Tropical medicine; Tumors
• ISSN: 1055-9965; 1538-7755
• DOI: 10.1158/1055-9965.EPI-07-0542

Although some high-risk ovarian cancer genes have been identified, it is likely that common low penetrance alleles exist that confer some increase in ovarian cancer risk. We have genotyped nine putative functional single-nucleotide polymorphisms (SNP) in genes involved in steroid hormone synthesis ( SRD5A2, CYP19A1, HSB17B1, and HSD17B4 ) and DNA repair ( XRCC2, XRCC3, BRCA2, and RAD52 ) using two Australian ovarian cancer case-control studies, comprising a total of 1,466 cases and 1,821 controls of Caucasian origin. Genotype frequencies in cases and controls were compared using logistic regression. The only SNP we found to be associated with ovarian cancer risk in both of these two studies was SRD5A2 V89L (rs523349), which showed a significant trend of increasing risk per rare allele ( P = 0.00002). We then genotyped another SNP in this gene (rs632148; r 2 = 0.945 with V89L) in an attempt to validate this finding in an independent set of 1,479 cases and 2,452 controls from United Kingdom, United States, and Denmark. There was no association between rs632148 and ovarian cancer risk in the validation samples, and overall, there was no significant heterogeneity between the results of the five studies. Further analyses of SNPs in this gene are therefore warranted to determine whether SRD5A2 plays a role in ovarian cancer predisposition. (Cancer Epidemiol Biomarkers Prev 2007;16(12):2557–9)